Articles On BARD1 Life Sciences (ASX:BD1)

Summary Australia-based medical diagnostics player BARD1 Life Sciences disclosed that its SubB2M technology showed remarkable specificity and sensitivity to detect breast cancer. BARD1 Life Sciences holds the exclusive worldwide licens...

BARD1 Life Sciences Ltd (ASX: BD1) shares are rocketing higher again today following the company’s latest positive report on its breast cancer testing technology. At the time of writing, the BARD1 share price is up 53.89% to $2.57. At one...

Bard1 (ASX:BD1) has picked up its run where it left off last week as investors hailed its latest clinical data. ... Read More The post Cancer diagnostics stock Bard1 gains another 40pc with more positive data appeared first on Stockhead.

Despite their rather unusual moniker, BARD1 Life Sciences Ltd [ASX:BD1] is making a name for themselves today. This small biotech stock is up 83.22% at time of writing... The post BARD1 Share Price is Up 83% Today — Here’s Why (ASX:BD1) ap...

The BARD1 Life Sciences Ltd (ASX: BD1) share price is up an eye-popping 66% at the time of writing. That’s down a bit from gains of more than 87% in early morning trade. Investor interest appears to be driven by the company’s positive anno...

Shares in cancer diagnostics company Bard1 (ASX:BD1) doubled this morning after new data was released on its ovarian cancer tech. ... Read More The post Bard1 Life Sciences shares double after ovarian cancer detection tech passes test with...

BARD1 Life Sciences (ASX: BD1) has unveiled “outstanding” preliminary test results showing its licenced SubB2M technology was a 100% specific in detecting all stages of ovarian cancer. Griffith University’s Institute of Glycomics has releas...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week We’re coming...

Australian medical technology companies Bard1 Life Sciences (ASX:BD1) and Sienna Cancer Diagnostics (ASX:SDX) have announced they will merge to create a new cancer...

Medical technology companies Bard1 Life Sciences (ASX: BD1) and Sienna Cancer Diagnostics (ASX: SDX) will stage a $23.7 million merger to create an Australian-based cancer diagnostics entity focused on addressing unmet needs in early cancer...

BARD1 Life Sciences (ASX:BD1), a medical technology company developing non-invasive cancer diagnostics, has announced the appointment of prominent Australian scientist Professor Allan Cripps as an Independent Non-Executive Director....

Yesterday, Stockhead reviewed the small caps that are devising treatments to fight cancer. There are also a handful of small caps that are seeking to help with diagnostics. In other words these small caps are either seeking to identify the...

Did you know that on this day last year those of you that were on this list at that time were given some pretty good mail on one of the best betting stings I've seen in the last decade. My mates from Sports Bet offered a market for some ran...

BARD1 Life Sciences (ASX:BD1), a medical technology company developing non-invasive cancer diagnostics, announced it has reached the phase three milestone of its contracted assay development program to transfer its BARD1 assay to th...

The science of Regenerative Medicine is a rapidly emerging field linking the medical technology, biotechnology and pharmaceutical sectors, and holds much potential to deliver better patient outcomes and drive economic growth.  Regenerative...

Eric Sprott is one of the world’s most prominent resources investors. Stockhead has decided to find which small caps he invests in. Sprott’s portfolio is dominated by Canadian listed Kirkland Lake Gold where until March he served as chairma...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

When your stock crashes you have three options: run away (and wait to claim the tax loss), sit still and hope things get better or ‘top up’. Speedcast’s (ASX: SDA) Peter Jackson bought $144,000 last week only a few weeks after it crashed. M...

In order to gain returns from the stock market, it is very important for investors to keep a track on stocks, which are making strong operational progress. The below-mentioned stocks have made substantial development in the recent past in t...

Medical science company Medlab Clinical (ASX: MDC) is steadily ticking boxes as it seeks regulatory clearance for its medicinal mouth spray product. The company announced this morning that it has ethics approval to run observational trial f...

Perth-based BARD1 Life Sciences (ASX:BD1), a medical technology company developing non-invasive cancer diagnostics, has updated investors on a number of initiatives.

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.